China
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment
Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies
Connect Biotech Scales Back in China, Reassesses Strategy for Asthma Drug to Compete with Dupixent
Connect Biotech, China workforce reduction, Dupixent rival, asthma drug strategy, biotech industry
HUTCHMED Withdraws Fruquintinib Application for Second-Line Gastric Cancer Treatment in China
HUTCHMED, fruquintinib, gastric cancer, second-line treatment, China, NDA withdrawal
ReNeuron Exits London Stock Exchange Amid Jacobio’s China Rights Deal
ReNeuron, Jacobio, London Stock Exchange, AIM, China rights deal, biotech, stem cell therapy
UCB Divests Mature Neurology and Allergy Portfolio in China for $680M
UCB, China, neurology, allergy, divestment, CBC Group, Mubadala, pharmaceuticals, innovation, strategic partnerships
UCB Divests Chinese Production Plant and Older Medications for $680 Million
UCB, production plant, older medications, China, $680M, pharmaceutical industry, divestment
Astellas Employee Indicted by China’s Prosecutors on Espionage Charges
Astellas Pharma, China, Japan, espionage, indictment, diplomatic tensions
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market